MX2022013160A - Heteroarilo halogenado y otros inhibidores de cinasas heterociclicas y usos de los mismos. - Google Patents
Heteroarilo halogenado y otros inhibidores de cinasas heterociclicas y usos de los mismos.Info
- Publication number
- MX2022013160A MX2022013160A MX2022013160A MX2022013160A MX2022013160A MX 2022013160 A MX2022013160 A MX 2022013160A MX 2022013160 A MX2022013160 A MX 2022013160A MX 2022013160 A MX2022013160 A MX 2022013160A MX 2022013160 A MX2022013160 A MX 2022013160A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- structurally similar
- inhibitors
- dasatinib
- abl
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 abstract 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 abstract 2
- 229960002448 dasatinib Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 206010000830 Acute leukaemia Diseases 0.000 abstract 1
- 208000034951 Genetic Translocation Diseases 0.000 abstract 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 abstract 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 abstract 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 1
- 102000055120 MEF2 Transcription Factors Human genes 0.000 abstract 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 abstract 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012641 Pigmentation disease Diseases 0.000 abstract 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 230000006750 UV protection Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a inhibidores de cinasa, en particular inhibidores de la proteína cinasas que incluye la superfamilia SIK CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT y/o sus mutantes. Aunque estructuralmente similares al dasatinib, los inhibidores de cinasa de la invención son distintivos; poseen una clase particular de heteroarilos halogenados. Estos inhibidores de cinasa pueden mostrar una o más ciertas propiedades distintas al dasatinib y otros inhibidores de cinasa estructuralmente similares. Los inhibidores de cinasa de la invención o composiciones farmacéuticas que los comprenden se pueden usar en el tratamiento de un trastorno o afección, tal como un trastorno proliferativo, por ejemplo, una leucemia o tumor sólido. En particular, estos y otros inhibidores de cinasa estructuralmente similares se pueden usar en el tratamiento de un trastorno proliferativo - tal como una leucemia aguda fenotípica mezclada (MPAL) - caracterizada por (entre otras cosas) la presencia de la proteína MEF2C, una translocación cromosómica humana en 11q23, y/o una oncoproteína de fusión KMT2A. Los inhibidores de cinasa o composiciones farmacéuticas descritas en la presente se pueden usar tópicamente para modular la pigmentación de la piel en un sujeto, por ejemplo para impartir protección UV y reducir el riesgo de cáncer de piel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20170641.3A EP3901151A1 (en) | 2020-04-21 | 2020-04-21 | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
PCT/EP2021/060338 WO2021214117A1 (en) | 2020-04-21 | 2021-04-21 | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013160A true MX2022013160A (es) | 2023-02-09 |
Family
ID=71108343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013160A MX2022013160A (es) | 2020-04-21 | 2021-04-21 | Heteroarilo halogenado y otros inhibidores de cinasas heterociclicas y usos de los mismos. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230348453A1 (es) |
EP (2) | EP3901151A1 (es) |
JP (1) | JP2023522124A (es) |
KR (1) | KR20230015343A (es) |
CN (1) | CN115667255A (es) |
AU (1) | AU2021258431A1 (es) |
BR (1) | BR112022021476A2 (es) |
CA (1) | CA3176325A1 (es) |
CL (1) | CL2022002899A1 (es) |
CO (1) | CO2022016245A2 (es) |
CR (1) | CR20220528A (es) |
IL (1) | IL297481A (es) |
MX (1) | MX2022013160A (es) |
PE (1) | PE20230462A1 (es) |
TW (1) | TW202204352A (es) |
WO (1) | WO2021214117A1 (es) |
ZA (1) | ZA202212631B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022369036A1 (en) * | 2021-10-19 | 2024-05-02 | Iomx Therapeutics Ag | A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof |
US20230210858A1 (en) * | 2022-01-05 | 2023-07-06 | The Board Of Regents Of The University Of Texas System | Podosomes as a therapeutic target for intracranial aneurysm |
EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4475916A (en) | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
JP2008528585A (ja) | 2005-01-26 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
EP3536323A1 (en) | 2014-08-08 | 2019-09-11 | Dana Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
CN106699744B (zh) * | 2015-11-18 | 2021-05-11 | 四川海思科制药有限公司 | 一种杂环类酰胺衍生物及其制备方法和在药学上的应用 |
US11285158B2 (en) | 2017-02-28 | 2022-03-29 | The General Hospital Corporation | Uses of pyrimidopyrimidinones as SIK inhibitors |
DK3391907T3 (da) | 2017-04-20 | 2020-03-09 | Iomx Therapeutics Ag | Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf |
EP3643713A1 (en) * | 2018-10-23 | 2020-04-29 | iOmx Therapeutics AG | Heterocyclic kinase inhibitors and uses thereof |
-
2020
- 2020-04-21 EP EP20170641.3A patent/EP3901151A1/en active Pending
-
2021
- 2021-04-21 PE PE2022002448A patent/PE20230462A1/es unknown
- 2021-04-21 US US17/996,514 patent/US20230348453A1/en active Pending
- 2021-04-21 KR KR1020227040346A patent/KR20230015343A/ko active Search and Examination
- 2021-04-21 TW TW110114388A patent/TW202204352A/zh unknown
- 2021-04-21 IL IL297481A patent/IL297481A/en unknown
- 2021-04-21 JP JP2022563872A patent/JP2023522124A/ja active Pending
- 2021-04-21 CN CN202180027921.5A patent/CN115667255A/zh active Pending
- 2021-04-21 CR CR20220528A patent/CR20220528A/es unknown
- 2021-04-21 AU AU2021258431A patent/AU2021258431A1/en active Pending
- 2021-04-21 MX MX2022013160A patent/MX2022013160A/es unknown
- 2021-04-21 EP EP21718920.8A patent/EP4139305A1/en active Pending
- 2021-04-21 CA CA3176325A patent/CA3176325A1/en active Pending
- 2021-04-21 BR BR112022021476A patent/BR112022021476A2/pt unknown
- 2021-04-21 WO PCT/EP2021/060338 patent/WO2021214117A1/en unknown
-
2022
- 2022-10-20 CL CL2022002899A patent/CL2022002899A1/es unknown
- 2022-11-11 CO CONC2022/0016245A patent/CO2022016245A2/es unknown
- 2022-11-21 ZA ZA2022/12631A patent/ZA202212631B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3901151A1 (en) | 2021-10-27 |
EP4139305A1 (en) | 2023-03-01 |
CA3176325A1 (en) | 2021-10-28 |
CO2022016245A2 (es) | 2023-02-27 |
IL297481A (en) | 2022-12-01 |
US20230348453A1 (en) | 2023-11-02 |
JP2023522124A (ja) | 2023-05-26 |
ZA202212631B (en) | 2023-07-26 |
CN115667255A (zh) | 2023-01-31 |
BR112022021476A2 (pt) | 2023-04-04 |
AU2021258431A1 (en) | 2022-11-17 |
KR20230015343A (ko) | 2023-01-31 |
WO2021214117A1 (en) | 2021-10-28 |
CL2022002899A1 (es) | 2023-06-30 |
TW202204352A (zh) | 2022-02-01 |
CR20220528A (es) | 2023-07-13 |
PE20230462A1 (es) | 2023-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013160A (es) | Heteroarilo halogenado y otros inhibidores de cinasas heterociclicas y usos de los mismos. | |
WO2021219731A3 (en) | Bicyclic kinase inhibitors and uses thereof | |
CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
CR20220614A (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
CR20200614A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
MX2019005834A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2. | |
TN2014000255A1 (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
IL251185A0 (en) | mek inhibitors and methods of using them | |
MX2022001940A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. | |
MX2022012178A (es) | Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso. | |
WO2005097137A3 (en) | Advanced quinazoline based protein kinase inhibitors | |
TW200512205A (en) | Quinazoline derivatives | |
BR0315912A (pt) | Compostos pirimìdicos com atividade antiproliferativa (ii) | |
PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
MX2022007155A (es) | Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos. | |
CR20220068A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
WO2019197605A3 (en) | Drug combinations for use in the treatment of ras-mutant cancer | |
MX2021004568A (es) | Inhibidores de cinasa heterociclicos y usos de los mismos. | |
MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. |